Tetracycline and Doxycycline Applications

Total Page:16

File Type:pdf, Size:1020Kb

Tetracycline and Doxycycline Applications RESIDENT COMPETITION: HONORABLE MENTION TETRACYCLINE AND DOXYCYCLINE APPLICATIONS Sean F. Lynn, MD ELSEVIER Tetracycline and doxycycline fre- sive antimicrobials. (Prim Care ABSORPTION AND EXCRETION quently are prescribed to women Update Ob/Gyns 1996;3:224-227) for a number of diflerent infec- Tetracycline is absorbed incom- tious diseases. Although both are pletely from the gastrointestinal tract; only 60% is absorbed under considered to be broad spectrum, The optimal and judicious selection optimal conditions. Plasma concen- many common pathogens have ac- of antimicrobial agents for the trations of doxycycline, however, quired resistance to them, leaving therapy of infectious disease is a essentially are equivalent whether a fairlyfinite list of indicated uses. complex procedure that requires This list includes the treatment of given orally or intravenously be- clinical judgment and detailed cause the drug’s absorption is several sexually transmitted dis- knowledge of pharmacological and nearly complete. The absorption of eases, pelvic inflammatory dis- microbiological factors. The goal is to both drugs is much greater in the ease and endometritis, and acne. choose a drug that is selectively ac- fasting state and is impaired sub- The principal contraindications to tive for the most likely infecting mi- stantially by food, milk products, their use are breast feeding, preg- croorganism(s) and that has the least antacids, calcium, and iron prepa- nancy, age less than 8 years, and potential to cause toxicity or allergic rations. Tetracycline is affected impaired renal or hepatic func- reactions in the individual being much more by these factors than tion. The main toxicities are stain- treated. Tetracycline and doxycy- doxycycline. Both tetracycline and ing of teeth, stippling of bones, and cline are antibiotics commonly pre- doxycycline should be taken 3 photosensitivity. Renal, central scribed by primary care physicians in hours before, or 2 hours after, taking nervous system, hepatic, and gas- the treatment of a number of infec- iron or antacids, and tetracycline trointestinal disturbances also tions. The objective of the following should not be taken with meals. have been documented. When Once in the serum, the half-lives of taken with food or certain medi- discussion is to review the pharma- tetracycline and doxycycline are cations, tetracycline is poorly ab- cology, toxicity, spectrum of activity, 6-1.2 hours and 16-18 hours, re- sorbed, making adequate serum clinical application, and cost of these spectively. Hence, tetracycline re- concentrations dificult to attain. important, and occasionally mis- quires four-times-a-day dosing, Doxycycline is better absorbed. used, antimicrobial agents. whereas doxycycline only needs to The volume of distribution for both be taken twice daily.2.3 drugs is essentially that of the The volume of distribution of tet- body’s serum, including small racyclines includes not only that of amountsin breastmilk, secretions, Pharmacology the extracellular serous fluid but the cerebrospinal fluid, and amniotic ORIGIN AND STRUCTURE tears, saliva, cerebrospinal fluid, fluid. The drugs are metabolized and amniotic fluid. Concentrations in the liver and then eliminated in The development of tetracycline an- in these secretions and fluids are the urine (tetracycline) or feces tibiotics was the result of a system- only IO-25% of those found in the (doxycycline). Subtle diflerences atic screening of soil specimens col- serum, and only doxycycline is in the metabolism and side eflects lected from many parts of the world known to accumulate in the cere- of the two medications favor the for antibiotic-producing organisms. brospinal fluid. All tetracyclines are use of doxycycline over tetracy- A number of tetracyclines exist, all concentrated in the liver and ex- cline in most instances. In spite Of very much alike in structure and creted by way of the bile into the their limitations, when used prop- function. Tetracycline and doxycy- intestine. Because of the effects of erly, tetracycline and doxycycline cline are semisynthetically pro- the enterohepatic circulation, the are safe, egective, and inexpen- duced from a species of Streptomy- tetracyclines are excreted and ces and differ only by the position of resorbed continually and thus may a single hydroxy moiety on carbon be present in the blood for a long From the Department of Obstetrics/Gynecology. tTniversity of Florida. Gainesville. Florida. #5.l time after cessation of therapy. Tet- 224 0 1996 Elsevier Science Inc.. all rights reserved. 1068-607X/96/$15.00 l PII SlO68-607X(96)00033-3 Prim Care Update ObiGyns TETRACYCLINE/DOXYCYCLINE racycline is eliminated primarily showed concentrations less than ing, and diarrhea may occur. Sev- through the kidney. Doxycycline, the lower limit of the sensitivity of eral studies cite tetracycline and on the other hand, is eliminated the assay. Nevertheless, the stan- doxycycline as the cause of revers- almost exclusively in the feces and dard of care presently is that tetra- ible esophageal ulcerations, pre- is, therefore, one of the safest of the cyclines should not be used by ventable, in part, by taking the med- antibiotics in the presence of renal breastfeeding mothers because al- ications in a sitting position and failure.lX3 ternative therapies are available and with a full glass of water. Alter- the potential implications are sig- ations in bowel flora may also cause MECHANISM OF ACTION nificant.’ bacterial overgrowth that can be life-threatening (see Superinfec- The site of action of tetracycline and CALCIFIED TISSUES tions). Overall, doxycycline is less doxycycline is the bacterial ribo- irritating to the gastrointestinal tract some. The drugs bind primarily to Retardation of bone growth and dis- than tetracycline.“,6.7 30 S ribosomes and block access of coloration of teeth may occur in bacterial aminoacyl tRNA to the children due to the formation of SUPERINFECTIONS acceptor sites on mRNA, preventing a tetracycline- or doxycycline- the addition of amino acids to the calcium complex. Whereas the ef- Like all antimicrobial agents, the growing peptide chain. Resistance fects on bone are reversible with tetracyclines may lead to superin- is mediated by a plasmid that pre- cessation of treatment, the tooth fections caused by resistant bacteria vents the intracellular accumula- discoloration is permanent. Tetra- or yeasts. The incidence of these tion of tetracyclines. These drugs cyclines are impregnated into tooth infections appears to be much are primarily bacteriostatic, pre- dentin and will fluoresce a bright higher with the tetracyclines than venting the organism from repro- yellow when exposed to ultraviolet with the penicillins. Pseudomem- ducing but not killing it outright. radiation and later stain a darker branous enterocolitis may occur Thus, an intact immune system is yellow or brown. Deciduous tooth with either oral or intravenous ad- necessary for eradication of the in- calcification occurs from the 14th ministration of tetracycline and fection.1.4 week in utero to 2-3 months of age. doxycycline.’ Tetracycline exposure during this time will affect only the deciduous HEPATIC Toxicity teeth. Permanent tooth calcification In general, tetracyclines should be takes place between the ages of 4 avoided in patients with hepatic REPRODUCTION months and 8 years?,” disease because of the catabolic or Tetracyclines are pregnancy cate- antianabolic effects that may yield a gory D, mainly due to their effects on SKIN nitrogen load requiring hepatic me- fetal bone and teeth (see below). Phototoxicity was noted to occur in tabolism. Fine vacuoles, cytoplas- Tetracyclines may reduce the effec- 40 of 2,682 (1.6%) patients treated mic changes, and increased deposi- tiveness of oral contraceptives; with tetracycline and six of 15 tion of fat have been noted to occur however, this effect has not been (40%) using doxycycline? This in the liver of patients treated with confirmed in all investigations.5B6 photosensitivity was evident only these drugs. Pregnant women are when skin was exposed to sunlight particularly susceptible to severe BREASTFEEDING containing rays in the range of tetracycline-induced hepatic inju- 270-320 nm range. This type of ry.2 Available data suggest that an insig- radiation is filtered out by ordinary nificant amount of tetracycline is window glass. All photosensitiza- NERVOUS SYSTEM excreted into breast milk. In addi- tion effects are reversible, and per- tion, one study showed that the Dizziness, tinnitus, and vertigo manent injury to the skin does not drug that is excreted is bound to have been reported and are com- occur.1*2.6 calcium, which retards its absorp- pletely reversible. Case reports of tion in the fetus. Review of the pseudotumor cerebri have also been literature shows that no cases of GASTROINTESTINAL associated with tetracycline use.’ tooth staining in breastfed infants The high antibiotic concentrations RENAL subsequent to maternal ingestion of reached in the intestine alter enteric tetracyclines have been well docu- flora, and stools may become soft, Tetracyclines may aggravate uremia mented. Assays on infants breastfed odorless, and yellow-green in color. in patients with renal disease be- by mothers using tetracyclines all Epigastric burning, nausea, vomit- cause, at higher concentrations, the 225 LYNN Table 1. Clinical Application of Tetracycline and Doxycycline in Obstetrics and Gynecology Dose and Duration of Condition Causative Organisms Therapy Remarks Acne (inflammatory
Recommended publications
  • The Role of Nanobiosensors in Therapeutic Drug Monitoring
    Journal of Personalized Medicine Review Personalized Medicine for Antibiotics: The Role of Nanobiosensors in Therapeutic Drug Monitoring Vivian Garzón 1, Rosa-Helena Bustos 2 and Daniel G. Pinacho 2,* 1 PhD Biosciences Program, Universidad de La Sabana, Chía 140013, Colombia; [email protected] 2 Therapeutical Evidence Group, Clinical Pharmacology, Universidad de La Sabana, Chía 140013, Colombia; [email protected] * Correspondence: [email protected]; Tel.: +57-1-8615555 (ext. 23309) Received: 21 August 2020; Accepted: 7 September 2020; Published: 25 September 2020 Abstract: Due to the high bacterial resistance to antibiotics (AB), it has become necessary to adjust the dose aimed at personalized medicine by means of therapeutic drug monitoring (TDM). TDM is a fundamental tool for measuring the concentration of drugs that have a limited or highly toxic dose in different body fluids, such as blood, plasma, serum, and urine, among others. Using different techniques that allow for the pharmacokinetic (PK) and pharmacodynamic (PD) analysis of the drug, TDM can reduce the risks inherent in treatment. Among these techniques, nanotechnology focused on biosensors, which are relevant due to their versatility, sensitivity, specificity, and low cost. They provide results in real time, using an element for biological recognition coupled to a signal transducer. This review describes recent advances in the quantification of AB using biosensors with a focus on TDM as a fundamental aspect of personalized medicine. Keywords: biosensors; therapeutic drug monitoring (TDM), antibiotic; personalized medicine 1. Introduction The discovery of antibiotics (AB) ushered in a new era of progress in controlling bacterial infections in human health, agriculture, and livestock [1] However, the use of AB has been challenged due to the appearance of multi-resistant bacteria (MDR), which have increased significantly in recent years due to AB mismanagement and have become a global public health problem [2].
    [Show full text]
  • National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): a Cross-Sectional Study
    Tropical Medicine and Infectious Disease Article National Antibiotic Consumption for Human Use in Sierra Leone (2017–2019): A Cross-Sectional Study Joseph Sam Kanu 1,2,* , Mohammed Khogali 3, Katrina Hann 4 , Wenjing Tao 5, Shuwary Barlatt 6,7, James Komeh 6, Joy Johnson 6, Mohamed Sesay 6, Mohamed Alex Vandi 8, Hannock Tweya 9, Collins Timire 10, Onome Thomas Abiri 6,11 , Fawzi Thomas 6, Ahmed Sankoh-Hughes 12, Bailah Molleh 4, Anna Maruta 13 and Anthony D. Harries 10,14 1 National Disease Surveillance Programme, Sierra Leone National Public Health Emergency Operations Centre, Ministry of Health and Sanitation, Cockerill, Wilkinson Road, Freetown, Sierra Leone 2 Department of Community Health, Faculty of Clinical Sciences, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone 3 Special Programme for Research and Training in Tropical Diseases (TDR), World Health Organization, 1211 Geneva, Switzerland; [email protected] 4 Sustainable Health Systems, Freetown, Sierra Leone; [email protected] (K.H.); [email protected] (B.M.) 5 Unit for Antibiotics and Infection Control, Public Health Agency of Sweden, Folkhalsomyndigheten, SE-171 82 Stockholm, Sweden; [email protected] 6 Pharmacy Board of Sierra Leone, Central Medical Stores, New England Ville, Freetown, Sierra Leone; [email protected] (S.B.); [email protected] (J.K.); [email protected] (J.J.); [email protected] (M.S.); [email protected] (O.T.A.); [email protected] (F.T.) Citation: Kanu, J.S.; Khogali, M.; 7 Department of Pharmaceutics and Clinical Pharmacy & Therapeutics, Faculty of Pharmaceutical Sciences, Hann, K.; Tao, W.; Barlatt, S.; Komeh, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown 0000, Sierra Leone 8 J.; Johnson, J.; Sesay, M.; Vandi, M.A.; Directorate of Health Security & Emergencies, Ministry of Health and Sanitation, Sierra Leone National Tweya, H.; et al.
    [Show full text]
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia
    PEER REVIEWED Use of Antibiotics to Prevent Calf Diarrhea and Septiceinia Peter D. Constable, BVSc, PhD, DACVIM Department of Veterinary Clinical Medicine, University of Illinois at Urbana-Champaign, Urbana, IL 61802 Abstract l'oxytetracycline (0.15 to 6.0 mg/lb [0.32 to 13.2 mg/kg] au 24 h, per os) sont efficaces dans le traitement de la This article reviews studies related to the use of diarrhee chez les veaux et permettent un accroissement antimicrobial agents to prevent calf diarrhea and septi­ du taux de croissance des veaux nourris au lait. De cemia, and discusses whether prophylactic administra­ plus, la chlortetracycline permet la diminution du taux tion of antibiotics in neonatal calves is effective and de mortalite lorsque administree chez les veaux indicated. Orally administered chlortetracycline, oxytet­ nouveau-nes pour prevenir la diarrhee. 11 n'y a pas racycline, tetracycline and neomycin have label claims d'antibiotiques qui promettent de prevenir la in the US for the "control" or "aid in the control" of calf septicemie chez les veaux. Paree qu'il ne semble pas diarrhea caused by bacteria susceptible to the antibi­ exister d'etudes sur l'efficacite de la tetracycline et de otic. Chlortetracycline and oxytetracycline (0.15 to 6.0 la neomycine et parce que !'utilisation hors homologa­ mg/lb [0.32 to 13.2 mg/kg], q 24 h, PO) are efficacious tion des medicaments. n'est pas permise pour la for preventing calf diarrhea and increasing growth rate prevention routiniere des maladies ou !'augmentation in milk-fed calves, and chlortetracycline (3 mg/lb [7 mg/ du taux de croissance et du taux de conversion kg], q 12 h, PO) is efficacious for decreasing mortality alimentaire, selon le code de l'AMDUCA de 1994, seule when administered to prevent diarrhea in neonatal !'administration orale de chlortetracycline et calves.
    [Show full text]
  • Sexually Transmitted Diseases Treatment Options
    Sexually transmitted disease (STD) treatment options PREFERRED & ALTERNATIVE OPTIONS Many clinical partners are operating in a limited capacity during the COVID-19 pandemic. Below are preferred (in clinic or other location where injections can be given) and alternative (when only oral medicines are available 1) treatments for STDs. Syndrome Preferred Treatments Alternative Treatments Follow-up Male urethritis syndrome Ceftriaxone 250mg intramuscular (IM) x 1 PLUS Men who have sex with men (MSM) and transgender women2: Patients should be counseled to azithromycin 1g PO x 1 Cefixime 800 mg PO x 1 PLUS doxycycline 100 mg PO BID x 7 days be tested for STDs once clinical Presumptively treating: care is resumed in the local If azithromycin is not available: doxycycline 100 Men who have sex with women only: gonorrhea clinics. Clients who have been mg PO BID for 7 days (except in pregnancy3) Cefixime 800mg PO x 1 PLUS azithromycin 1g PO x 1 referred for oral treatment If cephalosporin allergy5 is reported, gentamicin If cefixime is unavailable, substitute cefpodoxime 400mg PO q12h should return for 240mg IM x 1 PLUS azithromycin 2g PO x 1 x 2 for cefixime in above regimens4 comprehensive testing and screening and linked to services If oral cephalosporin not available or history of cephalosporin at that time. allergy5: azithromycin 2g PO x 1 If azithromycin is not available: doxycycline 100 mg PO BID for 7 days (except in pregnancy3) Patients should be advised to abstain from sex for 7 days Treatment typically guided by examination and For presumptive therapy when examination and laboratory following completion of Vaginal discharge syndrome treatment.
    [Show full text]
  • Long-Term Use of Spironolactone for Acne in Women: a Case Series of 403 Patients
    Long-term use of spironolactone for acne in women: A case series of 403 patients Vaibhav Garg, BS,a JulianaK.Choi,MD,PhD,b William D. James, MD,b and John S. Barbieri, MD, MBAb Philadelphia, Pennsylvania Background: There are limited data regarding the long-term outcomes of spironolactone use for women with acne and its effect on truncal acne. Objective: To comprehensively describe outcomes of patients treated with spironolactone in routine clinical practice, including long-term outcomes. Methods: We performed a retrospective case series of 403 adult women treated for acne with spironolactone at an academic medical center between 2008 and 2019. Rates of objective, as assessed by Comprehensive Acne Severity Scale scores, and subjective acne clearance were evaluated, as well as rates of treatment discontinuation, dosage changes, and drug survival. Logistic regression was used to assess for association between incidence of menstrual adverse effects and combined oral contraceptive use. Results: As evaluated by Comprehensive Acne Severity Scale scores, at the first follow-up, 75.5%, 84.0%, and 80.2% of patients with available data had reduction or complete clearance of acne on the face, chest, and back, respectively. The mean drug survival was 470.7 days. Menstrual adverse effects were less common among those using combined oral contraception (odds ratio, 0.23; 95% confidence interval, 0.11-0.50). Limitations: This study was conducted at a single academic medical center. Conclusions: Spironolactone improves clinical outcomes and is well tolerated for many adult women with acne using it for an extended duration. ( J Am Acad Dermatol 2021;84:1348-55.) Key words: acne; acne vulgaris; birth control pill; combined oral contraceptive; comprehensive acne severity scale; oral antibiotics; outcomes; spironolactone.
    [Show full text]
  • Doxycycline/Minocycline Step Therapy Criteria Program Summary
    Doxycycline/Minocycline Step Therapy Criteria Program Summary This criteria applies to Commercial, NetResults F series and Health Insurance Marketplace formularies. OBJECTIVE The intent of the Doxycycline/Minocycline Step Therapy (ST) program is to encourage the use of both cost-effective preferred doxycycline and minocycline products prior to the use of nonpreferred brand or generic doxycycline or minocycline products and to accommodate for use of brand nonpreferred doxycycline or minocycline products when the generic products cannot be used due to previous trial, documented intolerance, FDA labeled contraindication, or hypersensitivity. Requests for nonpreferred doxycycline and minocycline products will be reviewed when patient-specific documentation has been provided. TARGET DRUGS Doxycycline Products: Acticlate™ (doxycycline hyclate tablet) Adoxa (doxycycline monohydrate tablet, capsule) Doryx, Doryx MPC® (doxycycline hyclate delayed-release tablet)a Doxycycline (doxycycline hyclate delayed-release capsulea, doxycycline hyclate tablet, doxycycline monohydrate delayed release capsule) Monodox (doxycycline monohydrate capsule) Oracea (doxycycline monohydrate delayed-release capsule) Vibramycin (doxycycline hyclate capsule, doxycycline monohydrate suspension, doxycycline calcium syrup Minocycline Products: Minocin (minocycline capsule) minocycline tablet Solodyn (minocycline extended-release tablet)a a - available as a generic; designated target PRIOR AUTHORIZATION CRITERIA FOR APPROVAL Brand and Nonpreferred generic doxycycline and minocycline products will be approved when BOTH of the following are met: 1. ONE of the following: a. The patient’s medication history includes use of a preferred generic doxycycline product OR b. The patient has a documented intolerance, FDA labeled contraindication, or hypersensitivity to a preferred generic doxycycline product AND 2. ONE of the following is met: a. The patient’s medication history includes use of a preferred generic minocycline product OR b.
    [Show full text]
  • Prednisolone / Neomycin / Tetracycline For- Mulation
    SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 25.08.2020 3.6 09.04.2021 407521-00015 Date of first issue: 07.01.2016 SECTION 1: Identification of the substance/mixture and of the company/undertaking 1.1 Product identifier Trade name : Prednisolone / Neomycin / Tetracycline Formulation 1.2 Relevant identified uses of the substance or mixture and uses advised against Use of the Sub- : Veterinary product stance/Mixture 1.3 Details of the supplier of the safety data sheet Company : MSD 20 Spartan Road 1619 Spartan, South Africa Telephone : +27119239300 E-mail address of person : [email protected] responsible for the SDS 1.4 Emergency telephone number +1-908-423-6000 SECTION 2: Hazards identification 2.1 Classification of the substance or mixture Classification (REGULATION (EC) No 1272/2008) Skin sensitisation, Category 1 H317: May cause an allergic skin reaction. Reproductive toxicity, Category 1A H360D: May damage the unborn child. Effects on or via lactation H362: May cause harm to breast-fed children. Short-term (acute) aquatic hazard, Cate- H400: Very toxic to aquatic life. gory 1 Long-term (chronic) aquatic hazard, Cat- H410: Very toxic to aquatic life with long lasting egory 1 effects. 2.2 Label elements Labelling (REGULATION (EC) No 1272/2008) Hazard pictograms : Signal word : Danger Hazard statements : H317 May cause an allergic skin reaction. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H410 Very toxic to aquatic life with long lasting effects. 1 / 23 SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 25.08.2020 3.6 09.04.2021 407521-00015 Date of first issue: 07.01.2016 Precautionary statements : Prevention: P201 Obtain special instructions before use.
    [Show full text]
  • Staining and Hypoplasia of Enamel Caused by Tetracycline: Case Report P
    PEDIATRIC DENTISTRY/Copyright © 1987 by The American Academy of Pediatric Dentistry Volume 9 Number 3 Staining and hypoplasia of enamel caused by tetracycline: case report P. Fleming, BDentSc, FDS C.J. Witkop, Jr., DDS, MS W.H. Kuhlmann, DDS, MSD Abstract Case Report Staining of developing teeth due to tetracycline therapy A 23-year-old white male requested restoration of has been publicized widely. However, the ability of tetracy- his stained and hypoplastic anterior teeth (Fig 1). A clines to cause hypoplasia of enamel has not been accepted history revealed that between 2 and 3 years of age he had universally. This is a case report of enamel hypoplasia and received extensive tetracycline therapy for tonsillitis. staining presumably caused byahigh dosage of'tetracy'dines in There was no history of a prolonged fever at the time of childhood. Restoration of the teeth with bonded composite the illness. resins produced an esthetic result. -UK Schwachman and Schuster (1956) were the first to report unsightly staining of teeth due to tetracycline administered during the period of tooth formation in children with cystic fibrosis. This observation was con- y firmed by Zegarelli et al. (1961) who noted staining of the teeth in 38 of 52 cystic fibrosis patients who had been ijgj treated with large doses of antibiotics, frequently tetracy- .^••W^^ clines. With reports by Davies et al. (1962) and articles by Wallman and Hilton (1962) and Witkop and Wolf (1963) this complication of tetracycline therapy became widely recognized. FIG 1. Tetracycline staining and hypoplasia of the permanent Hypoplasia of enamel of the primary dentition asso- anterior teeth.
    [Show full text]
  • Prednisolone / Neomycin / Tetracycline For- Mulation
    SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.5 25.08.2020 407516-00013 Date of first issue: 07.01.2016 SECTION 1. PRODUCT AND COMPANY IDENTIFICATION Product name : Prednisolone / Neomycin / Tetracycline Formulation Manufacturer or supplier's details Company name of supplier : MSD Address : 2000 Galloping Hill Road Kenilworth - New Jersey - U.S.A. 07033 Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000 E-mail address : [email protected] Recommended use of the chemical and restrictions on use Recommended use : Veterinary product SECTION 2. HAZARDS IDENTIFICATION GHS Classification Skin sensitization : Category 1 Reproductive toxicity : Category 1A Effects on or via lactation Specific target organ toxicity : Category 2 (Kidney, inner ear) - repeated exposure Specific target organ toxicity : Category 2 (Gastrointestinal tract, Nervous system, Skin, Teeth) - repeated exposure (Oral) GHS label elements Hazard pictograms : Signal Word : Danger Hazard Statements : H317 May cause an allergic skin reaction. H360D May damage the unborn child. H362 May cause harm to breast-fed children. H373 May cause damage to organs (Kidney, inner ear) through prolonged or repeated exposure. H373 May cause damage to organs (Gastrointestinal tract, Nervous system, Skin, Teeth) through prolonged or repeated exposure if swallowed. Precautionary Statements : Prevention: P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. 1 / 24 SAFETY DATA SHEET Prednisolone / Neomycin / Tetracycline For- mulation Version Revision Date: SDS Number: Date of last issue: 23.03.2020 5.5 25.08.2020 407516-00013 Date of first issue: 07.01.2016 P260 Do not breathe dust.
    [Show full text]
  • Third ESVAC Report
    Sales of veterinary antimicrobial agents in 25 EU/EEA countries in 2011 Third ESVAC report An agency of the European Union The mission of the European Medicines Agency is to foster scientific excellence in the evaluation and supervision of medicines, for the benefit of public and animal health. Legal role Guiding principles The European Medicines Agency is the European Union • We are strongly committed to public and animal (EU) body responsible for coordinating the existing health. scientific resources put at its disposal by Member States • We make independent recommendations based on for the evaluation, supervision and pharmacovigilance scientific evidence, using state-of-the-art knowledge of medicinal products. and expertise in our field. • We support research and innovation to stimulate the The Agency provides the Member States and the development of better medicines. institutions of the EU the best-possible scientific advice on any question relating to the evaluation of the quality, • We value the contribution of our partners and stake- safety and efficacy of medicinal products for human or holders to our work. veterinary use referred to it in accordance with the • We assure continual improvement of our processes provisions of EU legislation relating to medicinal prod- and procedures, in accordance with recognised quality ucts. standards. • We adhere to high standards of professional and Principal activities personal integrity. Working with the Member States and the European • We communicate in an open, transparent manner Commission as partners in a European medicines with all of our partners, stakeholders and colleagues. network, the European Medicines Agency: • We promote the well-being, motivation and ongoing professional development of every member of the • provides independent, science-based recommenda- Agency.
    [Show full text]
  • 2021 Formulary List of Covered Prescription Drugs
    2021 Formulary List of covered prescription drugs This drug list applies to all Individual HMO products and the following Small Group HMO products: Sharp Platinum 90 Performance HMO, Sharp Platinum 90 Performance HMO AI-AN, Sharp Platinum 90 Premier HMO, Sharp Platinum 90 Premier HMO AI-AN, Sharp Gold 80 Performance HMO, Sharp Gold 80 Performance HMO AI-AN, Sharp Gold 80 Premier HMO, Sharp Gold 80 Premier HMO AI-AN, Sharp Silver 70 Performance HMO, Sharp Silver 70 Performance HMO AI-AN, Sharp Silver 70 Premier HMO, Sharp Silver 70 Premier HMO AI-AN, Sharp Silver 73 Performance HMO, Sharp Silver 73 Premier HMO, Sharp Silver 87 Performance HMO, Sharp Silver 87 Premier HMO, Sharp Silver 94 Performance HMO, Sharp Silver 94 Premier HMO, Sharp Bronze 60 Performance HMO, Sharp Bronze 60 Performance HMO AI-AN, Sharp Bronze 60 Premier HDHP HMO, Sharp Bronze 60 Premier HDHP HMO AI-AN, Sharp Minimum Coverage Performance HMO, Sharp $0 Cost Share Performance HMO AI-AN, Sharp $0 Cost Share Premier HMO AI-AN, Sharp Silver 70 Off Exchange Performance HMO, Sharp Silver 70 Off Exchange Premier HMO, Sharp Performance Platinum 90 HMO 0/15 + Child Dental, Sharp Premier Platinum 90 HMO 0/20 + Child Dental, Sharp Performance Gold 80 HMO 350 /25 + Child Dental, Sharp Premier Gold 80 HMO 250/35 + Child Dental, Sharp Performance Silver 70 HMO 2250/50 + Child Dental, Sharp Premier Silver 70 HMO 2250/55 + Child Dental, Sharp Premier Silver 70 HDHP HMO 2500/20% + Child Dental, Sharp Performance Bronze 60 HMO 6300/65 + Child Dental, Sharp Premier Bronze 60 HDHP HMO
    [Show full text]